Ultragenyx Pharmaceutical Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
During the three months ended September 30, 2025, the following directors and Section 16 officers adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Eric CrombezEVP, Chief Medical Officer | September 5, 2025 | Up to 45,238 shares | September 5, 2026 |
| Howard Horn, Chief Financial Officer and EVP, Corporate Strategy | September 2, 2025 | Up to 57,482 shares | September 2, 2026 |
| Shehnaaz Suliman, M.D., Ph.D.Board Member(1) | November 8, 2024, amended on September 15, 2025 | Up to 26,427 shares | September 15, 20261 |
(1)
On September 15, 2025, Dr. Suliman amended this Rule 10b5-1 trading arrangement to, among other things, amend the number of shares that could be sold under the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.